Among these changes, the decrease in digestive enzyme production stands out as particularly impactful for everyday comfort and nutritional health. While digestive difficulties might seem like an ...

Nonetheless, there might be individuals who naturally lack sufficient quantities of these enzymes, causing digestive problems including bloating, gas, and constipation. Enzyme supplements could ...

at the upcoming Digestive Disease Week Conference (DDW), to be held May 3-6, 2025, in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with ...

Enzymes also help with nerve function, respiration, digestion, muscle growth and much more. "The list is very long," says Farina. One of the things that makes enzymes unique is that they are not ...

Drug-resistant organisms kill an estimated 23,000 people in the U.S. every year, and it is predicted that by 2050 antimicrobial drug resistance will lead to more than 10 million deaths worldwide ...

IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible ...

The poster will be available for viewing during the DDW exhibition, and details are as follows: Title: Interim PK Data for SPY001, a Novel Half-Life Extended Monoclonal Antibody Targeting α4β7 ...

at the upcoming Digestive Disease Week Conference (DDW), to be held May 3-6, 2025, in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with ...

Phase 2 data presentation expands on top-line findings, reinforcing efimosfermin as a potential best-in-class FGF21 treatment for MASH Efimosfermin clinical program to advance to Phase 3 pivotal ...